Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2022-03-07 Earnings Release
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 7, 2022, reporting the financial results for the fourth quarter and year ended December 31, 2021. It specifically states that the financial results are provided via a press release attached as Exhibit 99.1. The document itself is a current report announcing the earnings release, not the earnings release report itself. The text is only 3734 characters, which is relatively short and mainly serves to announce the earnings results and attach the press release. According to the 'Menu vs Meal' rule, this is an announcement of the earnings release, not the earnings release itself. Therefore, the correct classification is Earnings Release (ER).
2022-03-07 English
CIDARA THERAPEUTICS, INC. 2021 FORM 10-K
Annual Report FY 2021
2022-03-07 English
FORM 8-K
Delisting Announcement Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 28, 2022, by Cidara Therapeutics, Inc. The content focuses on a notice received from Nasdaq regarding the company's failure to meet the minimum bid price requirement for continued listing, explaining the compliance period and potential delisting consequences. This is a regulatory announcement about the company's listing status, specifically a notice of potential delisting due to stock price falling below the required threshold. The document does not contain financial statements or detailed financial performance data, nor is it an earnings release or annual report. It is an official notice about the stock exchange listing status, which fits the definition of a Delisting Announcement (DLST). The document length is about 5,058 characters, sufficient to be a full announcement rather than a brief report publication announcement or regulatory filing. Therefore, the correct classification is DLST with high confidence.
2022-03-04 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-02-15 English
SC 13G/A
Major Shareholding Notification
2022-02-14 English
SCHEDULE 13G (AMENDMENT NO. 1)
Major Shareholding Notification
2022-02-14 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.